Literature DB >> 17854732

HIV/hepatitis coinfection in eastern Europe and new pan-European approaches to hepatitis prevention and management.

Jeffrey V Lazarus1, Priya B Shete, Irina Eramova, Simona Merkinaite, Srdan Matic.   

Abstract

ISSUES: HIV/hepatitis coinfection in Europe; WHO European clinical protocols on the management of people coinfected with HIV/AIDS and hepatitis B or C (HBV or HCV); stakeholder recommendations for better HCV services.
INTRODUCTION: The increasing availability of highly active antiretroviral therapy throughout Europe and central Asia has changed comorbidity and mortality patterns among people living with HIV/AIDS (PLWHA) as liver disease has increasingly replaced AIDS as the cause of death in PLWHA in western European countries. The average prevalence of HCV among PLWHA is 40 per cent, and much higher in countries where the HIV epidemic is driven by injecting drug use. Access to hepatitis treatment for PLWHA and IDUs is still very limited in Europe due to a lack of clear clinical management guidelines for HIV/hepatitis coinfections, high costs and a national failure to recognise hepatitis as a critical health issue. DESCRIPTION: In October 2006, the WHO Regional Office for Europe issued protocols for the clinical management of HIV/HCV and HIV/HBV coinfections. They include diagnostic algorithms adjusted for resource availability, and guidelines for the management of patients who do not yet need treatment, those who need only hepatitis or only HIV/AIDS treatment, and those who need both. Though the protocols should provide practical guidelines for physicians and assist in the development of national treatment standards, there is still a need for targeted prevention, treatment and care interventions. To expand access to hepatitis prevention and treatment, public awareness needs to be raised and national political leaders need to address hepatitis as a public health issue. Effective public health measures include price reductions for anti-hepatitis drugs; targeted testing, counselling and prevention activities; increased access to hepatitis B and C treatment and to HBV vaccination for the populations most at risk.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17854732     DOI: 10.1016/j.drugpo.2007.01.011

Source DB:  PubMed          Journal:  Int J Drug Policy        ISSN: 0955-3959


  8 in total

1.  Prevalence of HCV risk behaviors among prison inmates: tattooing and injection drug use.

Authors:  Marisol Peña-Orellana; Adriana Hernández-Viver; Glorimar Caraballo-Correa; Carmen E Albizu-García
Journal:  J Health Care Poor Underserved       Date:  2011-08

2.  Co-infections of tuberculosis, hepatitis B or C viruses in a cohort of people living with HIV/AIDS in China: predictors and sequelae.

Authors:  Chen Zhang; Xiaoming Li; Yu Liu; Shan Qiao; Yi Chen; Yuejiao Zhou; Zhiyong Shen
Journal:  AIDS Care       Date:  2016-12-21

3.  Exploring Patient Characteristics and Barriers to Hepatitis C Treatment in Patients on Opioid Substitution Treatment Attending a Community Based Fibro-scanning Clinic.

Authors:  Des Crowley; Walter Cullen; Eamon Laird; John S Lambert; Tina Mc Hugh; Carol Murphy; Marie Claire Van Hout
Journal:  J Transl Int Med       Date:  2017-06-30

4.  Hepatitis-C multimedia prevention program in poor Hispanic HIV-infected injecting drug users: six months after intervention.

Authors:  Angel M Mayor; Diana M Fernández; Héctor M Colón; James C Thomas; Christine Miranda; Robert F Hunter-Mellado
Journal:  J Health Care Poor Underserved       Date:  2013-11

Review 5.  Hepatitis C treatment access and uptake for people who inject drugs: a review mapping the role of social factors.

Authors:  Magdalena Harris; Tim Rhodes
Journal:  Harm Reduct J       Date:  2013-05-07

6.  Hepatitis B and C among patients infected with human immunodeficiency virus in Isfahan, Iran: seroprevalence and associated factors.

Authors:  Behrooz Ataei; Katayoon Tayeri; Nazila Kassaian; Ziba Farajzadegan; Anahita Babak
Journal:  Hepat Mon       Date:  2010-09-01       Impact factor: 0.660

7.  Prevalence of Viral Hepatitis B, C, and D in Kazakhstan.

Authors:  Almagul Jumabayeva; Alexander Nersesov; Maksut Kulzhanov; Margarita Nefedova; Gulsana Nuraliyeva; Gulnar Rakhimbekova; Shynar Tanabayeva; Ildar Fakhradiyev
Journal:  ScientificWorldJournal       Date:  2022-04-22

Review 8.  HBV Prevention and Treatment in Countries of Central Asia and the Caucasus.

Authors:  Daulet Amerzhanov; Indira Suleimenova; Salima Davlidova; Zhamilya Nugmanova; Syed Ali
Journal:  Viruses       Date:  2020-09-30       Impact factor: 5.048

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.